OnBioVC 1Q07 Summary

Here it is, hot off the press…An effort to aggregate all of the data that is found here at OnBioVC. To download the report please click (here) or paste the following link in your browser to grab the .pdf.:

http://ab.rubenstein.googlepages.com/home

Please forward all comments and criticisms to: arubenstein@rnaventures.com

Endocyte, Inc.: Series C $15M

Endocyte (West Lafayette, IN) developer of folate-targeted based therapeutics for the treatment of renal cell carcinoma, ovarian, endometrial and nscl cancer raised $15M in a Series C financing. Participants included Sanderling Ventures, Burrill & Company, Triathlon Medical Ventures, Blue Chip Venture Company, American Bailey Ventures and CID Capital.

MAP Pharmaceuticals, Inc.: Series D $50M

MAP Pharmaceuticals (Mountain View, CA) a product based biopharmaceutical focused on developing novel treatments for pediatric asthma and migraine therapy closed a $50M Series D financing. The deal was led by D.E. Shaw & Co. and was joined by Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital Partners, Bay City Capital and Skyline Ventures.

ChemoCentryx, Inc.: Series D $29.9M

ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases and oncology with lead indications for inflammatory bowel disease and multiple sclerosis, closed a $29.9M Series D finanicing. The deal was led by the Glaxo Group Ltd. and was joined by Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.

ProFibrix B.V.: Series A €8.5M

ProFibrix (Netherlands) a biotech company focused on fibrinogen-based products to stop surgical hemmoraging and initiate tissue repair, has closed a €8.5M Series A round. The deal was led by Index Ventures.

Numira Biosciences, Inc.: Series A $2.5M

Numira Biosciences (Irvine, CA) a medical device company specializing in high resolution bone imaging and virtual histology has raised a $2.5M Series A round. The deal was led by vSpring Capital and joined by Tech Coast Angels and Pasadena Angels.

Regado Biosciences, Inc.: Series C $23M

Regado Biosciences (Durham, NC) a biopharmaceutical company with a platform oligonucleotide drug-antidote pairing system focused upon the anticoagulant market has closed a $23M Series C financing. The deal was led by Caxton Advantage Life Sciences, Domain Associates, Quaker BioVentures and Aurora Funds.

Affinium Pharma, Inc.: Series A $18M

Affinium Pharmaceuticals (Canada) who is developing a new class of antibiotics targeting staph infections closed an $18M Series A financing. The deal was lead by Forward Ventures along with Oxford Bioscience , SV Life Sciences and Genesys Capital Partners.

CoreValve, Inc.: Series C Series C $33M

CoreValve (Irvine, CA) is a medical device company introducing a percutaneous revalving system to replace failing aortic heart valves without surgical access closed a $33M Series C financing. The deal was led by Maverick Capital other participants included Apax Partners, HealthCap and Sofinnova Partners.

Orqis Medical Corp.: Series D $37.4M

Orqis (Lake Forest, CA) is developing devices to prevent or reverse the underlying disease progression of congestive heart failure has closed a $37.4M Series D financing. New investors include Wasatch Advisors, Cross Creek Capital and the Omega Fund along with Boston Scientific and Lighthouse Capital Partners.